$BIVI

BioVie (NASDAQ:BIVI) will host an investor webinar on September 23, 2026, to discuss Phase 2 results of its drug bezisterim for Long COVID. CEO Cuong Do will present findings showing potential across key symptoms and discuss implications for neurological disorders. The company believes positive results could support bezisterim's development for multiple CNS conditions.

BioVie Inc. (BIVI) reported Phase 2 trial results for Bezisterim, showing significant improvements in Long COVID patients with high baseline fatigue and cognitive impairment. The drug demonstrated advantages over placebo on 21 of 22 endpoints and had a similar safety profile to placebo. BioVie plans to advance to Phase 3 trials. BIVI stock is down 8.23% in pre-market trading.

BioVie's lead drug, Bezisterim, showed improvements in fatigue, malaise, and brain fog in a long COVID clinical trial, according to CEO Cuong Do. The NIH has not seen similar results in other long COVID studies. BioVie plans to analyze biomarker data and seek FDA feedback for a Phase 3 trial. The company is also advancing Bezisterim for Parkinson's disease.

BIOVIE INC. (BIVI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry Into a Material Definitive Agreement. On September 11, 2026, BioVie Inc., a Nevada corporation (the “Company”), entered into a sales agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (the “Agent”), pursuant to which the Company may issue and

BioVie Inc. (BIVI, BIVIW) announced plans to advance its Phase 3 trial for bezisterim in Parkinson’s disease, with an End-of-Phase 2 meeting requested with the FDA. The trial will focus on motor symptoms (MDS-UPDRS Part III) as the primary endpoint, with non-motor symptoms (MDS-UPDRS Part I) as a co-primary or secondary endpoint. Phase 2 results suggested greater benefits for patients with higher inflammation levels. The company expects to discuss the trial design with the FDA later this year an

BioVie Inc (BIVI, BIVIW) completed its Phase 2 ADDRESS-LC trial for bezisterim in Long COVID patients, with topline results expected by September 2026. The study evaluates the drug's efficacy in improving neurological symptoms. The trial is fully funded by a U.S. Department of War grant. BioVie aims to address a condition affecting 17-20 million U.S. adults, with no FDA-approved treatments currently available.

Palumbo Joseph M (Chief Medical Officer) purchased 4,843 shares of BIOVIE INC. (BIVI) at $2.16 on 2026-08-28.

Chappell Amy Suzon purchased 727 shares of BIOVIE INC. (BIVI) at $2.16 on 2026-08-28.

KIM JOANNE WENDY (Chief Financial Officer) purchased 2,500 shares of BIOVIE INC. (BIVI) at $2.18 on 2026-08-28.

DO CUONG V (President & CEO) purchased 15,210 shares of BIOVIE INC. (BIVI) at $2.08 on 2026-08-27.